Form 13-F position report

ELICIO THERAPEUTICS INC

Reported by VANGUARD GROUP INC

ELTX CUSIP 28657F103 Manager CIK 0000102909

Reported 454,619 shares, up 132,925 (41.3%) from the prior quarter.

Reported value 77.1%; share count 41.3% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 454,619 Quarter-end amount reported
Reported value $3,509,658 Fair value at quarter end
Consecutive quarters held 9 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-06-30 672125
2023-09-30 1187453
2023-12-31 1458616
2024-03-31 1639214
2024-06-30 930080
2024-09-30 1233667
2024-12-31 1204533
2025-03-31 1981635
2025-06-30 3509658
2025-09-30 5184017
2025-12-31 3955331

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for ELICIO THERAPEUTICS INC held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Added 496,901 +23,042 (4.9%) < 0.01% $3,955,331 2026-01-29
Q3 2025 Added 473,859 +19,240 (4.2%) < 0.01% $5,184,017 2025-11-07
Q2 2025 Added 454,619 +132,925 (41.3%) < 0.01% $3,509,658 2025-08-11
Q1 2025 Added 321,694 +75,871 (30.9%) < 0.01% $1,981,635 2025-05-09
Q4 2024 Added 245,823 +561 (0.2%) < 0.01% $1,204,533 2025-02-11
Q3 2024 Added 245,262 +18,965 (8.4%) < 0.01% $1,233,667 2024-11-13
Q2 2024 Added 226,297 +10,611 (4.9%) < 0.01% $930,080 2024-08-13
Q1 2024 Added 215,686 +40,792 (23.3%) < 0.01% $1,639,214 2024-05-10
Q4 2023 Added 174,894 +34,367 (24.5%) < 0.01% $1,458,616 2024-02-14
Q3 2023 Added 140,527 +69,777 (98.6%) < 0.01% $1,187,453 2023-11-14
Q2 2023 New 70,750 +70,750 (0.0%) < 0.01% $672,125 2023-08-14

Who else reported the position

28 managers reported ELICIO THERAPEUTICS INC for Q2 2025.

Managers reporting ELICIO THERAPEUTICS INC in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Knoll Capital Management LLC Unchanged 630,915 0 3.46% $4,870,663 2 qtrs
VANGUARD GROUP INC This report Added 454,619 +132,925 < 0.01% $3,509,658 9 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 120,831 +43,364 < 0.01% $932,876 9 qtrs
NORTHERN TRUST CORPORATION Reduced 51,000 -855 < 0.01% $393,720 5 qtrs
BlackRock Inc Added 43,557 +4,234 < 0.01% $336,260 4 qtrs
CM Management LLC Reduced 25,000 -30,000 0.18% $193,000 9 qtrs
STATE STREET CORPORATION Unchanged 21,600 0 < 0.01% $166,752 6 qtrs
Quantinno Capital Management LP Unchanged 20,000 0 < 0.01% $154,400 2 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Reduced 17,023 -14,338 < 0.01% $131,418 2 qtrs
MEYER HANDELMAN CO Unchanged 13,899 0 < 0.01% $107,300 9 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 11, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
454,619

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.